News & Updates

January 1, 2020

Sage Group is working with medac GmbH who have developed Trecondi®, (Treosulfan), as a superior drug in conjunction with fludarabine prior to allogeneic hematopoetic stem cell transplantation (alloHSCT) in patients suffering from AML or MDS.

medac completed a European clinical study of 570 patients (NCT 00822393). This randomized Phase III trial was design...

December 2, 2019

BioHit Healthcare has developed and gained approval in Europe for the Acetium® lozenge. This binds cigarette smoke-derived acetaldehyde in the saliva, thus reducing the known effects of acetaldehyde in maintaining smoking dependence. Regular use of the Acetium® lozenge during smoking increased the likelihood of smoking cessation 1.5-fold compared with pla...

October 28, 2019

London, 28 October 2019. G-Med is the largest Online Global Medical Community for >1,000,000 physicians, from over 120  countries worldwide and 100 specialties. G-Med is the new "LinkedIn" for the physician and clinical community

G-Med is working with The Sage Group to identify global partners for service provision, collaboration and strategic partnerships...

August 30, 2019

WntResearch and The Sage Group have initiated a collaboration to accelerate the process of identifying and engaging potential partners prior to readout of the on-going Phase 2 study with Foxy-5.


Cancer is by far the largest research area in the pharmaceutical industry and the number of companies focusing on developing and commercializing new cancer treatm...

August 1, 2019

SAN DIEGO and PENNINGTON, N.J., May 29, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, and Emerge Health Pty (Emerge), the leading Australian company providing full registration, reimbursement, sales, marketing and distribution services of therapeutic products in Austra...

June 15, 2019

Sage is representing EpiAxis Therapeutics. We are seeking strategic partners to license their novel technology for epigenetic control of metastatic cancer.

EpiAxis Therapeutics is a leading epigenetics company targeting the nuclear bound lysine-specific demethylase 1 (LSD1) enzyme.  The company discovered the dual role that LSD1 plays in reprograming the e...

June 15, 2019

The Sage Group is representing Quest Consumer Health Holdings, the owner of the OraMelts manufacturing facility and patent portfolio, in their search for one or more partners with which it can collaborate to expand the applications of its unique and highly successful OraMelts oral adhesive disc drug delivery technology. Proprietary products using this tec...

December 26, 2018

The Sage Group Client Delcath Announces Commercial Licensing Agreement for CHEMOSAT® 7 Year Agreement with medac to Maximize Potential of CHEMOSAT in Europe

7 Year Agreement with medac to Maximize Potential of CHEMOSAT in Europe

Upfront and Milestone Payments Provide Additional Resources to Advance Clinical Development in the U.S.

NEW YORK (December 20, 2018...

Please reload